The effort to develop novel therapies for incremental survival gains overlooks a major opportunity. Simply ensuring patients can afford and access existing care through financial support could potentially yield equivalent or greater survival improvements, reframing the value and urgency of addressing financial toxicity.

Treat patient initiatives not as single-use projects tied to a drug launch, but as long-term, sustainable assets. Design programs with an eye toward future applicability for other drugs, therapeutic areas, or geographies. This approach maximizes the return on investment and creates an institutional capability.

By negotiating prices down from over $1,000 to as low as $150 per month, the government deal fundamentally shifts Ozempic's market position. It is no longer a high-end luxury akin to plastic surgery but an accessible wellness product comparable to a fancy gym membership, dramatically expanding its addressable market.

The common misconception is that market access teams just set prices. In reality, they are a complete business leadership team with diverse expertise in health economics, strategy, and outcomes research. They must understand the entire business environment to demonstrate a therapy's value and ensure its commercial success, operating far beyond a simple pricing role.

Bio CEO John Crowley defines "winning" in the biotech race as a two-part victory. It's not enough to lead in scientific discovery; the US must also dismantle systemic barriers like insurance hurdles and high out-of-pocket costs to ensure Americans can access these advanced medicines.

Administering complex biologics at home via on-body devices can bridge significant healthcare disparities. This model can eliminate the physical, financial, and geographic barriers faced by patients in rural areas or those reliant on caregivers for transport to infusion centers.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

The company's approach to Alzheimer's is a complete system, not just a drug. By leveraging Roche's diagnostic arm, they are pairing a new treatment with a simple, blood-based biomarker test for primary care physicians. This strategic pairing enables earlier patient identification, creating a more effective and accessible treatment paradigm.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.